517 related articles for article (PubMed ID: 19465233)
21. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience.
Bonds DE; Craven TE; Buse J; Crouse JR; Cuddihy R; Elam M; Ginsberg HN; Kirchner K; Marcovina S; Mychaleckyj JC; O'Connor PJ; Sperl-Hillen JA
Diabetologia; 2012 Jun; 55(6):1641-50. PubMed ID: 22450889
[TBL] [Abstract][Full Text] [Related]
22. Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy.
Harmer JA; Keech AC; Veillard AS; Skilton MR; Marwick TH; Watts GF; Meredith IT; Celermajer DS;
Atherosclerosis; 2015 Sep; 242(1):295-302. PubMed ID: 26233916
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial.
Margolis KL; O'Connor PJ; Morgan TM; Buse JB; Cohen RM; Cushman WC; Cutler JA; Evans GW; Gerstein HC; Grimm RH; Lipkin EW; Narayan KM; Riddle MC; Sood A; Goff DC
Diabetes Care; 2014 Jun; 37(6):1721-8. PubMed ID: 24595629
[TBL] [Abstract][Full Text] [Related]
24. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Anand SS; Bosch J; Eikelboom JW; Connolly SJ; Diaz R; Widimsky P; Aboyans V; Alings M; Kakkar AK; Keltai K; Maggioni AP; Lewis BS; Störk S; Zhu J; Lopez-Jaramillo P; O'Donnell M; Commerford PJ; Vinereanu D; Pogosova N; Ryden L; Fox KAA; Bhatt DL; Misselwitz F; Varigos JD; Vanassche T; Avezum AA; Chen E; Branch K; Leong DP; Bangdiwala SI; Hart RG; Yusuf S;
Lancet; 2018 Jan; 391(10117):219-229. PubMed ID: 29132880
[TBL] [Abstract][Full Text] [Related]
25. Is fenofibrate a cost-saving treatment for middle-aged individuals with type 2 diabetes? A South African private-sector perspective.
Wessels F
Cardiovasc J Afr; 2010; 21(1):43-6. PubMed ID: 20224845
[TBL] [Abstract][Full Text] [Related]
26. Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study.
Papademetriou V; Lovato L; Tsioufis C; Cushman W; Applegate WB; Mottle A; Punthakee Z; Nylen E; Doumas M;
Am J Nephrol; 2017; 45(2):136-145. PubMed ID: 27992863
[TBL] [Abstract][Full Text] [Related]
27. Medical strategies to reduce amputation in patients with type 2 diabetes.
Malik RA; Tesfaye S; Ziegler D
Diabet Med; 2013 Aug; 30(8):893-900. PubMed ID: 23445087
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
[TBL] [Abstract][Full Text] [Related]
29. Fibrates and microvascular complications in diabetes--insight from the FIELD study.
Ansquer JC; Foucher C; Aubonnet P; Le Malicot K
Curr Pharm Des; 2009; 15(5):537-52. PubMed ID: 19199980
[TBL] [Abstract][Full Text] [Related]
30. Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study.
Sullivan D; Forder P; Simes J; Whiting M; Kritharides L; Merrifield A; Donoghoe M; Colman PG; Graham N; Haapamäki H; Keech A;
Diabetes Res Clin Pract; 2011 Nov; 94(2):284-90. PubMed ID: 21862166
[TBL] [Abstract][Full Text] [Related]
31. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study.
Ong KL; Januszewski AS; O'Connell R; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Hung WT; Scott RS; Taskinen MR; Keech AC; Rye KA
Diabetologia; 2015 Mar; 58(3):464-73. PubMed ID: 25425220
[TBL] [Abstract][Full Text] [Related]
32. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Burgess DC; Hunt D; Li L; Zannino D; Williamson E; Davis TM; Laakso M; Kesäniemi YA; Zhang J; Sy RW; Lehto S; Mann S; Keech AC
Eur Heart J; 2010 Jan; 31(1):92-9. PubMed ID: 19797259
[TBL] [Abstract][Full Text] [Related]
33. Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
d'Emden MC; Jenkins AJ; Li L; Zannino D; Mann KP; Best JD; Stuckey BG; Park K; Saltevo J; Keech AC;
Diabetologia; 2014 Nov; 57(11):2296-303. PubMed ID: 25149070
[TBL] [Abstract][Full Text] [Related]
34. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
Chew EY; Davis MD; Danis RP; Lovato JF; Perdue LH; Greven C; Genuth S; Goff DC; Leiter LA; Ismail-Beigi F; Ambrosius WT;
Ophthalmology; 2014 Dec; 121(12):2443-51. PubMed ID: 25172198
[TBL] [Abstract][Full Text] [Related]
35. Risk of lower limb amputation in a national prevalent cohort of patients with diabetes.
Gurney JK; Stanley J; York S; Rosenbaum D; Sarfati D
Diabetologia; 2018 Mar; 61(3):626-635. PubMed ID: 29101423
[TBL] [Abstract][Full Text] [Related]
36. Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD.
Ferreira JP; Vasques-Nóvoa F; Ferrão D; Saraiva F; Falcão-Pires I; Neves JS; Sharma A; Rossignol P; Zannad F; Leite-Moreira A
Diabetes Care; 2022 Jul; 45(7):1584-1591. PubMed ID: 35320363
[TBL] [Abstract][Full Text] [Related]
37. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study.
Mohammedi K; Woodward M; Hirakawa Y; Zoungas S; Colagiuri S; Hamet P; Harrap S; Poulter N; Matthews DR; Marre M; Chalmers J;
Cardiovasc Diabetol; 2016 Sep; 15(1):129. PubMed ID: 27590190
[TBL] [Abstract][Full Text] [Related]
38. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
Collins R; Armitage J; Parish S; Sleigh P; Peto R;
Lancet; 2003 Jun; 361(9374):2005-16. PubMed ID: 12814710
[TBL] [Abstract][Full Text] [Related]
39. A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
Steiner G
Treat Endocrinol; 2005; 4(5):311-7. PubMed ID: 16185099
[TBL] [Abstract][Full Text] [Related]
40. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Scott R; O'Brien R; Fulcher G; Pardy C; D'Emden M; Tse D; Taskinen MR; Ehnholm C; Keech A;
Diabetes Care; 2009 Mar; 32(3):493-8. PubMed ID: 18984774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
